Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL5667 Target Snapshot

Phosphatidylinositol 5-phosphate 4-kinase type-2 beta · SINGLE PROTEIN · Homo sapiens

389Compounds
124Assays
4Approved Drugs
209.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt P78356. Use UniProt P78356 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt P78356 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Phosphatidylinositol 5-phosphate 4-kinase type-2 beta as ChEMBL target CHEMBL5667, mapped to UniProt P78356. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Phosphatidylinositol 5-phosphate 4-kinase type-2 beta
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL5667
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P78356
Phosphatidylinositol 5-phosphate 4-kinase type-2 beta
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Phosphatidylinositol 5-phosphate 4-kinase type-2 beta is the right protein anchor across sources, using UniProt P78356 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelPhosphatidylinositol 5-phosphate 4-kinase type-2 beta
UniProt AccessionP78356
Component TypeProtein
Sequence Length416 aa

Phosphatidylinositol 5-phosphate 4-kinase type-2 beta

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Phosphatidylinositol 5-phosphate 4-kinase type-2 beta, mapped to UniProt P78356. Sequence length is 416 aa.

Mapped IDP78356
Review namePhosphatidylinositol 5-phosphate 4-kinase type-2 beta
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

4
Approved
3
Phase III
6
Phase II
2
Phase I
Assay Mix

Activity Type Distribution

IC5089.0
KD120.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL502835 7.77 Kd 17.0 Approved
CHEMBL603469 7.75 Kd 18.0 Clinical
CHEMBL5271804 7.52 IC50 30.0 Preclinical
CHEMBL535 7.41 Kd 39.0 Approved
CHEMBL388978 7.11 Kd 77.0 Preclinical
CHEMBL1908397 7.03 Kd 94.0 Preclinical
CHEMBL572878 6.85 Kd 140.0 Clinical
CHEMBL1287853 6.8 Kd 160.0 Approved
CHEMBL1721885 6.58 Kd 260.0 Clinical
CHEMBL522892 6.58 Kd 260.0 Clinical
Distribution

pChEMBL Value Distribution

14
5.0
10
5.5
2
6.0
10
6.5
6
7.0
4
7.5
0
8.0
0
8.5
0
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

FEDRATINIB
CHEMBL1287853
Approved 2019
MIDOSTAURIN
CHEMBL608533
Approved 2017
NINTEDANIB
CHEMBL502835
Approved 2014
SUNITINIB
CHEMBL535
Approved 2006
Assay Landscape

Assay Landscape

124
Total Assays
60
Tested Compounds
1
Assay Types
Binding — 124 assays, 60 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 69 55 5.7
assay format 24 5 5.0
subcellular format 18 0
cell-based format 13 0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine